Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05813366
Other study ID # P.T.REC/012/003877
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 25, 2023
Est. completion date July 25, 2023

Study information

Verified date April 2023
Source Cairo University
Contact Nahla Mohamed Ashour
Phone 01050069089
Email nashour@horus.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome (PMS) affecting up to 8% of reproductive age women. It is characterized by physical and psychological symptoms that occur in the luteal phase of the menstrual cycle, prior to the onset of menses, and leads to negative impact on the psychosocial functioning of affected individuals. Selective serotonin reuptake inhibitors are usually used to treat PMDD but they have several side effects so it is important to use complementary treatment such as tryptophan-rich diet and acupuncture for women with PMDD . The purpose of the current study is to determine the combined effect of tryptophan-rich diet and acupuncture on depression related to premenstrual dysphoric disorder


Description:

This study will be conducted on 39 participants suffering from premenstrual dysphoric disorder (PMDD). They will be recruited from Horus University, New Damietta, Egypt.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 39
Est. completion date July 25, 2023
Est. primary completion date June 25, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 30 Years
Eligibility Inclusion Criteria: - All females will be clinically diagnosed with premenstrual dysphoric disorder (PMDD) as confirmed and referred from the gynaecologist. - All females will be firstly assessed by Hamilton Depression rating scale (HDRS) for two months to confirm depression related to PMDD before participating in the study. - Their ages will be ranged from 20 to 30 years. - Their BMI will be ranged from 20 to 25 kg/m. - Being virgin. - Having regular menstruation for the last 6 months (every 28- 35 days with no intermittent bleeding). - All females have a sedentary lifestyle. - Voluntary acceptance of participation in the study Exclusion Criteria: - Using hormonal contraception (such as oral contraceptives and injections). - Menstrual irregularity. - Using diuretics or psychiatric medications. - Using chronic non-steroidal anti-inflammatory drugs. - Pre-diagnosed with any other psychological problems not related to PMDD. - Follow any exercise programs.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Acupuncture
Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
Tryptophan-Rich Diet
All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc. Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed.
Vitamin B6 Supplementation
All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Outcome

Type Measure Description Time frame Safety issue
Primary The Premenstrual Symptoms Screening Tool (PSST) It is a validated, simple, user-friendly screening tool to identify women who suffer from severe Premenstrual Syndrome (PMS) or Premenstrual Dysphoric Disorder (PMDD). It reflects and 'translates' categorical Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria into a rating scale with degrees of severity (Not at all, mild, moderate, severe). The scoring will be as follows:
the following criteria must be present for a diagnosis of PMDD:
At least one of #1, #2, #3, and #4 is severe.
In addition at least four of #1 - #14 are moderate to severe.
At least one of A, B, C, D and E is severe.
Up to 2 months
Primary Hamilton Depression Rating Scale (HDRS) The HDRS (also known as the Ham-D) is the most widely used clinician-administered depression assessment scale. HRSD provides a reliable and valid assessment of depression.
Method for scoring varies by version. For the HDRS17, a score of 0 - 9 is generally accepted to be within the normal range, 10 - 13 mild, 14-17 mild to moderate and >17 moderate to severe
Up to 2 months
Secondary Quality of Life Enjoyment and Satisfaction Questionnaire - short form It evaluates overall enjoyment and satisfaction with physical health, mood, work, household and leisure activities, social and family relationships, daily functioning, sexual life, economic status, overall well-being and medications.
Responses are scored on a 5-point scale ("very poor" to "very good"), where higher scores indicate better enjoyment and satisfaction with life (possible range 14-70). Previous study had shown that it is reliable, valid and sensitive assessments of the individuals' quality of life (QOL)
Up to months 2
See also
  Status Clinical Trial Phase
Completed NCT03862469 - Premenstrual Hormonal and Affective State Evaluation (PHASE) Project N/A
Active, not recruiting NCT00536198 - Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder N/A
Completed NCT03449979 - Single Session of tACS in a Depressive Episode N/A
Completed NCT00516113 - A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria Phase 4
Recruiting NCT05098574 - Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder Phase 2
Withdrawn NCT04123483 - EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders Phase 4
Completed NCT00518570 - Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD) N/A
Not yet recruiting NCT01217775 - Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder Phase 3
Terminated NCT02362191 - Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD N/A
Completed NCT00678574 - The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder Phase 4
Active, not recruiting NCT05327075 - Premenstrual Dysphoric Disorder:Knowledge,Attitude and Practice Among Egyptian Females
Not yet recruiting NCT02448836 - Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD) N/A
Completed NCT01799733 - Alternative Treatments for Premenstrual Dysphoric Disorder N/A
Completed NCT06227676 - Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25 Phase 2/Phase 3
Active, not recruiting NCT02508103 - Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study Phase 2/Phase 3
Completed NCT00927095 - Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD) Phase 4
Completed NCT00089414 - Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives Phase 2
Completed NCT01875718 - A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD) Phase 1/Phase 2
Completed NCT06136104 - The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms N/A
Completed NCT01385709 - The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels N/A